Treatment of Relapsed or Refractory Multiple Myeloma With BCMA ...

Mitigating Toxicities Will Position BCMA for Role in Triple-Class ...

Targeting BCMA has shifted the development of chimeric antigen receptor (CAR) T-cell therapies for patients with relapsed or refractory multiple ...

Preclinical assessment of LCAR-B38M, a novel BCMA-targeting ...

Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma. Xiaohu ...

Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes ...

“Abecma is an important treatment option for patients with triple-class exposed relapsed and refractory multiple myeloma who have received at ...

Release Details - Poseida Therapeutics, Inc.

New clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session.

Effects of Consolidation Therapy With Autologous Hematopoietic ...

Despite the success of chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory multiple myeloma (RRMM), failure after CAR ...

Management of Adverse Reactions for BCMA-Directed Therapy in ...

Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody–drug conjugates, and chimeric antigen receptor T ...

652. Multiple Myeloma - Abstract

Bispecific antibodies (BsAb) are a new effective treatment for relapsed/refractory multiple myeloma (RRMM). Although these immunotherapies are ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) is the first BCMA ...

In February 2022, the U.S. FDA initially approved cilta-cel for the treatment of adults with relapsed or refractory multiple myeloma after four ...

BCMA loss in the epoch of novel immunotherapy for multiple myeloma

In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/ ...

Comprehensive meta-analysis of anti-BCMA chimeric antigen ...

Anti-BCMA CAR T therapy is effective and safe for patients with R/R MM. It can improve the prognosis of patients with high-risk cytogenetic features.

Class comparison of BCMA-directed therapies in relapsed multiple ...

This retrospective study evaluated the efficacy of BCMA-directed therapies in relapsed multiple myeloma (MM) patients, focusing on antibody ...

Clinical Trials Using Cevostamab - NCI

This phase II trial tests how well cevostamab after BCMA chimeric antigen receptor (CAR) T cell therapy works in treating patients with multiple myeloma that ...

FDA approves GSK's BLENREP (belantamab mafodotin-blmf) for the ...

BLENREP is the first approved anti-BCMA therapy and has the potential to transform the treatment of patients with relapsed or refractory myeloma ...

How do I treat patients with RRMM after failure of BCMA-targeted ...

... relapse with BCMA-targeted therapies, including CAR T-cell therapies, bispecific antibodies, and antibody−drug ... Multiple Myeloma Hub•13K views.

Blenrep-Based Combo Provides Survival Benefit in Relapsed ...

Treatment for relapsed or refractory multiple myeloma includes anti-CD38 antibodies, immunomodulating agents, CAR-T cell therapies, and ...

Belantamab Mafodotin Triplet Improves OS in Relapsed/Refractory ...

In the open-label, multicenter phase 3 DREAMM-7 trial, 494 patients with previously treated relapsed/refractory multiple myeloma were randomly ...

Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P ...

Patients with relapsed/refractory (r/r) multiple myeloma (MM) have several treatment options, from chemotherapy regimens to several FDA-approved ...

Triplet regimen extends OS in relapsed or refractory multiple myeloma

The analysis included 494 adults with multiple myeloma who received at least one prior line of therapy. Participants had not received prior B- ...

What treatment options are available for relapsed and refractory ...

4.5K subscribers in the multiplemyeloma community. This subreddit is for the discussion of multiple myeloma, myeloma related news, ...

Relapsed Refractory Multiple Myeloma | Current Treatment Options

In the first portion, hosted by Nina Shah, MD, Professor of Clinical Medicine, Multiple Myeloma Translational Initiative, ...